CBD study for baby seizures halted early
NCT ID NCT04485104
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a cannabidiol (CBD) oral solution in children under 2 years old with tuberous sclerosis complex, Dravet syndrome, or Lennox-Gastaut syndrome who had uncontrolled seizures. The goal was to see if CBD is safe and can reduce seizures. However, the study was terminated early after enrolling only 3 participants, so we have very little information about how well it works or its risks in this young age group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
cannabidiol (CBD) oral solution
What this could lead to
If successful, this could provide a treatment option to reduce seizures in very young children with these rare conditions.
What could go wrong
The study was terminated early with only 3 participants, so results are very limited. It is unclear if CBD is safe or effective in this age group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEIZURE IN PARTICIPANTS WITH TUBEROUS SCLEROSIS COMPLEX are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Little Rock, Arkansas, 72202, United States
-
Clinical Trial Site
Los Angeles, California, 90095, United States
-
Clinical Trial Site
Chicago, Illinois, 60611, United States
-
Clinical Trial Site
Boston, Massachusetts, 02114, United States
-
Clinical Trial Site
Cincinnati, Ohio, 45229, United States
-
Clinical Trial Site
Houston, Texas, 77030, United States
-
Clinical Trial Site
Florence, 50139, Italy
-
Clinical Trial Site
Genova, 16147, Italy
-
Clinical Trial Site
Rome, 00165, Italy
-
Clinical Trial Site
Barcelona, 08950, Spain
-
Clinical Trial Site
Madrid, 28034, Spain